Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schneebaum, S.
Right arrow Articles by Skornik, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schneebaum, S.
Right arrow Articles by Skornik, Y.

Annals of Surgical Oncology, Vol 4, Issue 5 371-376, Copyright © 1997 by Society of Surgical Oncology

ARTICLES

Radioimmunoguided surgery benefits for recurrent colorectal cancer

S. Schneebaum, J. Papo, M. Graif, M. Baratz, J. Baron and Y. Skornik
Department of Surgery A, Ichilov Hospital, Tel-Aviv Sourasky Medical Center, Israel.

BACKGROUND: Despite new adjuvant therapy, 50% of patients with colon cancer will have recurrent disease. This study investigated the use of a radiolabeled monoclonal antibody in locating occult tumor during surgery for recurrent colorectal cancer. METHODS: Twenty-two patients with recurrent colorectal cancer underwent surgery using the radioimmunoguided surgery (RIGS) system. All patients were subjected to abdominal and chest computed tomography (CT). Before surgery, patients were injected with the CC49 monoclonal antibody (MoAb), anti-TAG antibody labeled with 125I. Ten patients with elevated carcinoembryonic antigen (CEA) levels and no CT findings had a scintigraphy scan with an anti-CEA MoAb labeled with 99Tc. Human antimouse antibody levels of these patients were within normal limits. Surgical exploration including liver ultrasound examination was followed by survey with a gamma-detecting probe (GDP). RESULTS: There was MoAb tumor localization in 100% of the patients. CT found nine tumor sites, traditional surgical exploration 30, and the GDP 51, with 44 confirmed by pathology (hematoxylin and eosin). The RIGS system found occult tumor in 10 patients (45.4%) and resulted in major changes in surgical procedure in 11 patients. In the 10 patients who had scintigraphy scans, 10 tumor sites were identified, whereas RIGS found an additional eight sites. CONCLUSION: RIGS technology offers a substantial benefit for patients undergoing surgery for recurrent colorectal cancer and a better chance of finding recurrent tumor intraoperatively in patients who have elevated CEA levels with no other CT findings.


This article has been cited by other articles:


Home page
 Cancer Res.Home page
K. T. Moesta, B. Ebert, T. Handke, D. Nolte, C. Nowak, W. E. Haensch, R. K. Pandey, T. J. Dougherty, H. Rinneberg, and P. M. Schlag
Protoporphyrin IX Occurs Naturally in Colorectal Cancers and Their Metastases
Cancer Res., February 1, 2001; 61(3): 991 - 999.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
J. C. Kim, W. S. Kim, J. S. Ryu, S. J. Oh, D. H. Lee, K. H. Koo, S. A. Roh, H. C. Kim, C. S. Yu, G. H. Kang, et al.
Applicability of Carcinoembryonic Antigen-specific Monoclonal Antibodies to Radioimmunoguided Surgery for Human Colorectal Carcinoma
Cancer Res., September 1, 2000; 60(17): 4825 - 4829.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the Society of Surgical Oncology.